Five-year Clinical Outcomes of CAD Patients Complicated with Diabetes after StentBoost-optimized Percutaneous Coronary Intervention
Publication date: September 2019Source: Chinese Medical Sciences Journal, Volume 34, Issue 3Author(s): Qiang Chen, Liwei Zhang, Dangsheng Huang, Chunhong Zhang, Qiushuang Wang, Dong Shen, Minjun Xiong, Feifei YangObjectiveTo evaluate the instant effects and five-year clinical outcomes of coronary artery disease patients complicated with diabetes mellitus after StentBoost-optimized percutaneous coronary intervention (PCI).MethodsFrom March 2009 to July 2010, 184 patients undergoing PCI at our hospital were found stent underexpansion or malapposition by StentBoost after stents implantation and were divided into the diabetic (n=73, 39.67%) and the non-diabetic group (n=111, 60.33%). All patients received StentBoost-guided post-dilatation after stent implantation. The instant procedural results were measured and clinical outcome after five-year follow-up was analyzed in each group. Between-group comparisons were performed using Chi-square test or Student's t test. Multivariate logistic regression analysis was carried out to reveal the independent predictors for long-term clinical outcomes of StentBoost-optimized PCI.ResultsAfter StentBoost-guided post-dilatation, the minimum diameter (MinLD), maximum diameter (MaxLD) and average diameter in both groups increased significantly than before (P
Abstract BACKGROUND: Antithrombotic therapies that are optimal for atrial fibrillation (AF) patients undergoing percutaneous coronary intervention (PCI) have been studied but remain uncertain. We often encounter difficulties in choosing an appropriate antithrombotic therapy with antiplatelet agents after PCI in AF patients treated with oral anticoagulant due to a high CHADS2 score. Since there are no data on the incidences of PCI procedures in AF patients, we evaluated those incidences as well as the association between PCI and the CHADS2 score using data from the Fushimi AF Registry. METHODS: The Fushimi AF ...
Authors: Nikulina S, Artyukhov I, Shesternya P, Gavrilyuk O, Maksimov V, Voyevoda M, Brusentsov D Abstract The aim of the present study was to investigate the susceptibility of two coronary artery disease (CAD)-associated single nucleotide polymorphisms on 9p21 (rs1333049 and rs10757278) to myocardial infarction (MI) in a primary (stratification of high risk group for MI) and secondary prevention setting. The prospective observational study included 500 patients with MI [411 males (82.2%) and 89 females (17.8%)] under 65 years. The risk of MI for carriers of the homozygous CC genotype of rs1333049 and homozygous GG...
CONCLUSION: Our findings suggest that DM negatively affects aortic dilatation during an earlier phase of atherosclerosis progression and positively affects the progression of aortic calcification in a later phase. PMID: 31554764 [PubMed - as supplied by publisher]
CONCLUSIONS: The present study showed that EAT was an independent predictor of coronary thrombus burden in STEMI. PMID: 31544899 [PubMed - as supplied by publisher]
ConclusionIn patients with ACS undergoing PCI, CHA2DS2-VASc score can be used as a novel, simple and a sensitive diagnostic tool for the prediction of CIN.
CONCLUSION: The occurrence of pathological FFR values, most frequently documented in the LAD, was the same in patients with or without HFrEF, HFpEF, diabetes mellitus, AF, and LVH, demonstrating that these comorbidities did not influence FFR values and, thus, the indication for PCI. PMID: 31485776 [PubMed - as supplied by publisher]
Publication date: Available online 1 September 2019Source: The LancetAuthor(s): Deepak L Bhatt, Philippe Gabriel Steg, Shamir R Mehta, Lawrence A Leiter, Tabassome Simon, Kim Fox, Claes Held, Marielle Andersson, Anders Himmelmann, Wilhelm Ridderstråle, Jersey Chen, Yang Song, Rafael Diaz, Shinya Goto, Stefan K James, Kausik K Ray, Alexander N Parkhomenko, Mikhail N Kosiborod, Darren K McGuire, Robert A HarringtonSummaryBackgroundPatients with stable coronary artery disease and diabetes with previous percutaneous coronary intervention (PCI), particularly those with previous stenting, are at high risk of ischaemic even...
Conditions: Diabetes Mellitus; Microvascular Coronary Artery Disease Interventions: Drug: Ticagrelor; Drug: Clopidogrel Sponsors: Region Skane; IHF GmbH - Institut für Herzinfarktforschung; Hippocrates Research; IRW consulting AB; AstraZeneca Not yet recruiting